Alfresa Holdings Corporation
2784・Prime Market・Wholesale Trade
Business
Alfresa Holdings is a holding company comprising four business segments: wholesale distribution of prescription pharmaceuticals and medical devices (through a nationwide network centered on Alfresa Corporation), wholesale distribution of self-medication products such as OTC drugs (Alfresa Healthcare), manufacturing and sale of pharmaceuticals, active pharmaceutical ingredients, and medical devices (Alfresa Pharma), and pharmacy operation (Apoc Create). Of net sales of ¥3,104,064 million, approximately 89% is accounted for by the prescription pharmaceutical wholesale business, which serves hospitals, clinics, pharmacies, and other medical institutions as its main customers. The company is also expanding into new areas such as regenerative medicine supply chains and CDMO operations, and is promoting the establishment of a Total Supply Chain Service (TSCS) that provides integrated support spanning pharmaceutical development, manufacturing, distribution, and post-marketing surveillance.
Business Model
Main revenue source is the procurement/wholesale distribution margin on prescription pharmaceuticals and other products, with a low-margin, high-volume model recording net sales of ¥3,104,064 million against total purchases of ¥2,900,101 million. This is combined with the manufacturing business (Alfresa Pharma's proprietary products, active pharmaceutical ingredients, and contract manufacturing) and the dispensing pharmacy business (Apocrit) to diversify revenue across the entire value chain. Value is enhanced through limited distribution handling of specialty pharmaceuticals and M&A of medical device specialty trading companies, while distribution quality is differentiated through the promotion of ISO9001 certification.
Company Strengths
Alfresa Group commands the industry's largest number of MS (pharmaceutical wholesale sales representatives) and is advancing its Neo-Primary strategy. It has achieved high sales growth in the clinic sales channel, with pharmaceutical wholesale business sales for FY2026 (ending March 2026) reaching ¥2,782,584 million (up 5.4% year on year), outpacing overall market growth.
The company has continued M&A activity involving specialized medical device distributors, including making Miyano Medix and East Japan Medical System subsidiaries in September 2025 and making Techno Suzuta a wholly owned subsidiary in March 2026. It is progressively expanding its nationwide medical device distribution network, strengthening the medical product distribution function within TSCS.
The Group has an integrated structure covering everything from drug development support and manufacturing (Alfresa Pharma), to logistics and wholesale sales (Alfresa), post-marketing surveillance (ArkMS), and dispensing pharmacies (Apokuriito). Through PATH-Solution, launched in January 2026, it provides comprehensive support for overseas emerging biopharmaceutical companies entering the Japanese market, building integrated capabilities that are difficult for other companies to replicate in a short period.
ENVALITH's Perspective
Performance Trend
Revenue increased for five consecutive fiscal years, rising from ¥2,585,643 million in FY2022 to ¥3,104,064 million in FY2026. Operating profit, however, peaked at ¥38,460 million in FY2024 before declining for two consecutive years to ¥38,080 million in FY2025 and ¥36,164 million in FY2026, with the operating margin falling to 1.2%. Net income of ¥41,746 million in FY2026 was up 52.4% year on year, but this was primarily driven by a one-off factor: a ¥25,331 million gain on sales of investment securities (from a reduction in cross-shareholdings). External factors, including the negative impact of the April 2025 mid-year drug price revision and rising logistics and labor costs, weighed on profits. Operating cash flow improved substantially to ¥38,566 million, and the financial position remains sound. For FY2027, net income is forecast to decline sharply to ¥20,800 million (down 50.2% year on year), a period in which the company's underlying earning power will be tested once the extraordinary gains fall away.
Growth Strategy
TSCS aims to diversify earnings toward FY2028 (ending March 2028) through business expansion and evolution, entry into biosimilar manufacturing, and new business investments
Leveraging the industry's largest-scale MS (medical sales representatives) to increase handling of specialty pharmaceuticals and limited-distribution products, achieving sales growth that exceeds market growth. Results are already becoming apparent, with pharmaceutical wholesale business sales in FY2026 (ending March 2026) up 5.4% year on year.
Established a CDMO company for the manufacture of biosimilar drug substances and formulations through a four-party joint venture with Kids Well Bio Corporation, Chiome Bioscience Inc., and Mycenax Biotech Inc. Aims to improve domestic self-sufficiency, establish a stable supply system, and pursue overseas exports.
To address drug lag/loss issues, provides an end-to-end platform supporting overseas emerging biopharmaceutical companies from market analysis through development, regulatory affairs, manufacturing, sales, and post-marketing surveillance. Being developed as a new revenue source for TSCS (Toho Sales & Customer Solutions).
Made Miyano Medics (Hiroshima), Higashi Nihon Medical System (Sendai), and Techno Suzuta (Nagasaki) subsidiaries, strengthening the distribution function for medical products at TSCS. Aims to contribute to regional healthcare and expand the revenue base of the wholesale business.
Proceeding with the sale of cross-held shares (proceeds of ¥30,924 million in FY2026, ending March 2026) to improve capital efficiency. As a subsequent event, resolved in May 2026 to conduct a share buyback via FCSR method with an upper limit of ¥15,000 million and up to 6,307,800 shares, strengthening shareholder returns.
Last updated: July 19, 2026